Hola,
Are you new here?

ONCOMIRS

financed

MicroRNAs and Cancer From Bench to Bedside

Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that specific microRNAs (miRs) and molecules involved in their biogenesis contribute to tumorigenesis. The ONCOMIRS consortium pro... see more

31/01/2013

VLAAMS INSTITUUT...

4M€

Project Budget: 4M€

Project leader

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 7 Participantes

Financing granted El organismo FP7 notifico la concesión del proyecto The day 2013-01-31 We do not have the information of the call

0% 70% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

7 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

0.00€ | Leader

CNRS

N.D. | participant

FUNDACIO PRIVADA CENTRE DE R...

N.D. | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project leader

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 4M€

participation deadline Sin fecha límite de participación.

Project description Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that specific microRNAs (miRs) and molecules involved in their biogenesis contribute to tumorigenesis. The ONCOMIRS consortium proposes a natural succession of four experimental strategies. Fist, we will DISCOVER and unveil novel miRs and components of their biogenesis machinery and investigate links between these molecules and human cancers. Secondly, we will CONNECT the information obtained on deregulated miRs with known cellular pathways involved in cancer, such as the p53 tumour suppressor pathway. This will be conducted using both forward experimentations, in which targets mRNA are experimentally identified for a number of miR aetiologically related to cancer, and reverse experimentations in which mouse models and cell lines with abrogated tumour suppressor pathways or activated oncogenes are used. To establish a causal relationship between dysregualted miRs and cancer development we will MODEL the tumorigenic processes in mice lacking or overexpressing particular miRs. Finally, since the specificity and potency of some miRs suggest that they might be promising as THERAPEUTIC agents, these models will be used in conjunction with other cancer models to explore miR-based therapeutic strategies.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers